Chapter 6 174 transformed to ensure that the data met the assumptions of the statistical analyses. Changes in sleep architecture were analyzed using linear mixed models in Rstudio (version 1.3.1093) using packages lme4 (Bates et al., 2015) and lmerTest (Kuznetsova et al., 2017). To estimate changes in sleep architecture after 3 months of GAHT, a model was constructed with the sleep outcomes per night (SOL, TST, WASO, SE, NRI, NRA, SWS, SWS%, REM sleep latency and REM sleep duration) as outcome variables, timepoint (e.g. baseline or 3 months of GAHT) as the fixed predictor and a random intercept per participant to adjust for repeated measures within participants. Since a number of participants reported the use of psychotropic medication, we conducted an additional sensitivity analysis in which we adjusted for the use of psychotropic medication by adding this as a covariate in the model. To correct for repeated testing of the main results, Bonferroni correction was applied to all the main analyses, resulting in a corrected p-value threshold of 0.0025. 3. Results 3.1. Demographic and clinical characteristics Figure 6.1 displays the sample size of the full RESTED study and the sample size of the current study. The total study sample of the current study consists of 38 transmasculine participants, of whom 36 contributed data in the baseline measurement and 26 contributed data at the 3-month followup, and 35 transfeminine participants, of whom 32 contributed data to the baseline measurement and 24 contributed data to the 3-month follow-up measurement. In order to use the available data in the most optimal manner, all available data was used, including data from participants whose data was only present in one of the two measurements. As displayed in Table 6.1, transmasculine participants’ median age at baseline was 23 and transfeminine participants’ median age at baseline was 26. At baseline, 17% of transmasculine and 12% of transfeminine participants used psychotropic medication, most commonly antidepressants (11% in transmasculine and 9% in transfeminine participants) and stimulants (6% in transmasculine and 6% in transfeminine participants).
RkJQdWJsaXNoZXIy MTk4NDMw